CD19 and diffuse large B-cell lymphoma: Notably, FMC63 is the single-chain variable fragment (scFv) of the anti-CD19 antibody present in all FDA-submitted CTL019 products registered for treatment of r/r DLBCL, including Tisagenlecleucel (Kymriah©), Axicaptagene ciloleucel (Yescarta©), and Lisocabtagene maraleucel (Breyanzi©, JCAR017) [27].